INPP5D and carcinoma: Interestingly, not only is the mutation status of SHIP1 very low in B-ALL cases, but the other components of the PI3K/AKT/mTOR signaling pathway are also much less frequently affected by mutations compared to other types of leukemia or carcinomas.